Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: This double-blind placebo-controlled paralleled study randomized 302 patients with type 2 diabetes (mean A1C 8.3%) on metformin monotherapy (mean 1.5 g/day) to receive one of five INCB13739 doses or placebo once daily for 12 weeks. The primary end point was the change in A1C at study end. Other end points included changes in fasting glucose, lipids, weight, adverse events, and safety. RESULTS: CONCLUSIONS:
|
Authors | Julio Rosenstock, Salomon Banarer, Vivian A Fonseca, Silvio E Inzucchi, William Sun, Wenqing Yao, Gregory Hollis, Robert Flores, Richard Levy, William V Williams, Jonathan R Seckl, Reid Huber, INCB13739-202 Principal Investigators |
Journal | Diabetes care
(Diabetes Care)
Vol. 33
Issue 7
Pg. 1516-22
(Jul 2010)
ISSN: 1935-5548 [Electronic] United States |
PMID | 20413513
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Enzyme Inhibitors
- Hypoglycemic Agents
- INCB 13739
- Placebos
- Sulfonamides
- Metformin
- 11-beta-Hydroxysteroid Dehydrogenase Type 1
|
Topics |
- 11-beta-Hydroxysteroid Dehydrogenase Type 1
(antagonists & inhibitors)
- Administration, Oral
- Adolescent
- Adult
- Aged
- Diabetes Mellitus, Type 2
(drug therapy)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Enzyme Inhibitors
(administration & dosage, adverse effects)
- Humans
- Hyperglycemia
(drug therapy)
- Hypoglycemic Agents
(administration & dosage)
- Metformin
(administration & dosage)
- Middle Aged
- Placebos
- Sulfonamides
(administration & dosage, adverse effects)
- Treatment Outcome
- Young Adult
|